What if a pill you take for diabetes could also protect your brain from Alzheimer's? That's the question Novo Nordisk A/S (NVO) is about to answer, and the results could redefine how we think about treating one of medicine's most devastating diseases.
Early next month, Novo will present findings from late-stage trials testing whether Rybelsus—its oral diabetes medication containing semaglutide, the same ingredient in Ozempic and Wegovy—can slow cognitive decline in people with mild Alzheimer's. The company will unveil the data on December 3 at the Clinical Trials on Alzheimer's Disease meeting in San Diego.
The stakes are high. According to Reuters, if Rybelsus demonstrates close to a 30% reduction in cognitive decline, experts would view it as a clear win. Even more modest results could inform how future trials are designed or how the drug might work alongside existing Alzheimer's treatments.
A Lottery Ticket With Scientific Backing
Novo has described these trials—which the company itself likened to a "lottery ticket"—as potentially pivotal. The studies are enrolling thousands of participants with mild Alzheimer's to determine whether the medication can reduce cognitive decline by at least 20%, Reuters reported.
Here's why this matters: Alzheimer's affects an estimated 50 million people worldwide, and treatment options remain frustratingly limited. Positive results would introduce a convenient oral medication for a neurodegenerative disease that desperately needs better solutions. Citing experts, Reuters noted that success could fundamentally reshape the treatment landscape.
The Evidence Trail
The idea didn't come out of nowhere. Much of the rationale behind these trials emerged from research involving diabetes patients, who showed reduced dementia risk when treated with GLP-1 drugs. Novo launched the Alzheimer's studies in 2021 after animal research and analyses of human data suggested potential cognitive benefits.
A small study of liraglutide, the company's older injectable GLP-1, also reported slower loss of brain volume in patients with mild Alzheimer's. That earlier finding helped build the case for testing semaglutide in larger, more definitive trials.
The biological mechanisms remain somewhat mysterious. GLP-1 drugs might directly affect the brain, or the benefits could come from weight loss and reduced inflammation. Interestingly, not all GLP-1 drugs behave identically—preclinical studies suggest liraglutide enters the brain more readily than semaglutide, according to Reuters.
The Current Landscape
Right now, only two Alzheimer's-slowing drugs have regulatory approval: Eli Lilly and Co.'s (LLY) Kisunla and Leqembi from Eisai and Biogen Inc (BIIB). Both require infusions or injections and carry risks of serious side effects, making an effective oral alternative particularly appealing.
The upcoming data will either validate Novo's bet on repurposing a diabetes drug for brain health or send researchers back to the drawing board. Either way, December 3 promises to be an important day in Alzheimer's research.
